Nu-Med Plus, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nu-Med Plus, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Apr 19, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Apr 13, 2016 |
| FY2014 | Dec 31, 2013 | $0 | Mar 23, 2015 |
| FY2013 | Dec 31, 2012 | $0 | Feb 21, 2014 |
| FY2012 | Dec 31, 2011 | $0 | Mar 28, 2013 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($56.2K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($68.3K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($125.5K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($130.2K) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($830.1K) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($2.01M) | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | ($1.04M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.19M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.58M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $9.65M | Apr 3, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($49.0K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($63.3K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($120.5K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($182.2K) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($839.4K) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($1.99M) | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | ($1.02M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.17M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($466.5K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($1.22M) | Apr 3, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $66.2K | Feb 21, 2014 |
| FY2013 | Dec 31, 2012 | $22.1K | Feb 21, 2014 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($48.0K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($4.4K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($66.4K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($38.5K) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($206.8K) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($414.8K) | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | ($567.3K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($467.6K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($430.5K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($180.3K) | Apr 3, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $0 | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | ($5.0K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 1, 2019 |
| FY2015 | Dec 31, 2015 | $0 | Apr 13, 2016 |
| FY2015 | Dec 31, 2014 | ($1.1K) | Apr 13, 2016 |
| FY2014 | Dec 31, 2013 | $28.9K | Mar 23, 2015 |
| FY2013 | Dec 31, 2012 | $18.8K | Feb 21, 2014 |
| FY2012 | Dec 31, 2011 | $554 | Mar 28, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.9K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $9.4K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $13.5K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $79.5K | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $22.2K | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $557.1K | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | $45.8K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $423.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $406.7K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $35.5K | Apr 3, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $279.2K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $224.5K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $160.2K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $142.6K | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $154.5K | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $89.4K | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | $416.2K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $374.5K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $338.5K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $4.47M | Apr 3, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($271.3K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($215.1K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | ($146.8K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | ($63.0K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($132.4K) | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | $467.7K | Apr 3, 2023 |
| FY2020 | Dec 31, 2019 | ($370.4K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $48.5K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $68.2K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($4.44M) | Apr 3, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.95M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($9.89M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($9.82M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($9.70M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($9.57M) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($8.74M) | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | ($6.73M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($5.69M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($4.50M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($8.08M) | Apr 3, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.4K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $6.8K | Mar 31, 2025 |
| FY2021 | Dec 31, 2020 | $188.5K | Apr 11, 2022 |
| FY2021 | Dec 31, 2019 | $7.1K | Apr 11, 2022 |
| FY2020 | Dec 31, 2018 | $167.5K | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $351.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $12.5K | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | $30.9K | Apr 3, 2018 |
| FY2016 | Dec 31, 2014 | $56.3K | Apr 19, 2017 |
| FY2015 | Dec 31, 2013 | $13.2K | Apr 13, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 3, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 3, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 83.55M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 83.55M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 83.55M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 81.35M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 79.35M | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | 51.03M | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | 44.48M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 41.27M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 37.56M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 37.24M | Apr 3, 2018 |